Pfizer Inc (PFE): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Pfizer ( PFE) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 3.3%. By the end of trading, Pfizer rose $0.38 (1.2%) to $31.22 on average volume. Throughout the day, 27,807,065 shares of Pfizer exchanged hands as compared to its average daily volume of 26,149,200 shares. The stock ranged in a price between $30.61-$31.28 after having opened the day at $30.84 as compared to the previous trading day's close of $30.84. Other companies within the Drugs industry that increased today were: Cytokinetics ( CYTK), up 26.1%, Arrowhead Research Corporation ( ARWR), up 18.6%, Sunesis Pharmaceuticals ( SNSS), up 18.3% and Puma Biotechnology ( PBYI), up 18.2%.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $198.6 billion and is part of the health care sector. Shares are up 0.7% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Prima Biomed ( PBMD), down 17.6%, Prana Biotechnology ( PRAN), down 8.8%, La Jolla Pharmaceutical ( LJPC), down 8.2% and Alliqua ( ALQA), down 4.8%.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Profit With Technical Analysis: Cramer's 'Mad Money' Recap (Tuesday 2/20/18)

Profit With Technical Analysis: Cramer's 'Mad Money' Recap (Tuesday 2/20/18)

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

Axovant Shares Crater as CEO and President Both Resign

Axovant Shares Crater as CEO and President Both Resign